Cargando…

The potential benefits of a national vaccine registry for Canada

Detalles Bibliográficos
Autores principales:	Gorfinkel, Iris S., Lexchin, Joel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	CMA Joule Inc. 2021
Materias:	Letters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8177937/ https://www.ncbi.nlm.nih.gov/pubmed/34059499 http://dx.doi.org/10.1503/cmaj.78920

Ejemplares similares

Using bar codes to create a robust national vaccine registry
por: Gorfinkel, Iris
Publicado: (2021)

Enabling Patient Portals to Access Primary Care Medical Records: Maximizing Collaboration in Care between Patients and Providers
por: GorFinkel, Iris, et al.
Publicado: (2019)

Health Canada: optimizing transparency and its impact for patients
por: Abi-Jaoude, Elia, et al.
Publicado: (2021)

Time to Marketing of Generic Drugs After Patent Expiration in Canada
por: Lexchin, Joel
Publicado: (2021)

Time to potential for listing of new drugs on public and private formularies in Canada: a cross-sectional study
por: Lexchin, Joel
Publicado: (2022)

A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada
por: Morgan, Steven G., et al.
Publicado: (2016)

Canada and the pharmaceutical industry in the time of COVID-19
por: Lexchin, Joel
Publicado: (2023)

National patient groups in Canada and their disclosure of relationships with pharmaceutical companies: a cross-sectional study
por: Lexchin, Joel, et al.
Publicado: (2022)

Marketing before patenting: implications for price controls in Canada
por: Lexchin, Joel
Publicado: (2010)

Health Canada's Proposal to Accelerate New Drug Reviews
por: Lexchin, Joel
Publicado: (2020)

Development Time and Patent Extension for Prescription Drugs in Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2020)

COVID-19 Vaccination in Romania and the Benefits of the National Electronic Registry of Vaccinations
por: Enciu, Bianca Georgiana, et al.
Publicado: (2023)

Canada and access to medicines in developing countries: intellectual property rights first
por: Lexchin, Joel
Publicado: (2013)

It’s Time to Finally Kill the Zombies Comment on "Universal Pharmacare in Canada"
por: Lexchin, Joel
Publicado: (2020)

'Linkage' pharmaceutical evergreening in Canada and Australia
por: Faunce, Thomas A, et al.
Publicado: (2007)

Time to market for drugs approved in Canada between 2014 and 2018: an observational study
por: Lexchin, Joel
Publicado: (2021)

Canada's Patented Medicine Notice of Compliance regulations: balancing the scales or tipping them?
por: Lexchin, Joel
Publicado: (2011)

After More Than 50 Years, Pharmacare (and Dental Care) are Coming to Canada
por: Lexchin, Joel
Publicado: (2022)

Donations Made and Received: A Study of Disclosure Practices of Pharmaceutical Companies and Patient Groups in Canada
por: Lexchin, Joel
Publicado: (2021)

Health Canada's use of its priority review process for new drugs: a cohort study
por: Lexchin, Joel
Publicado: (2015)

How Safe and Innovative Are First-in-Class Drugs Approved by Health Canada: A Cohort Study
por: Lexchin, Joel
Publicado: (2016)

Pharmaceutical company spending on research and development and promotion in Canada, 2013-2016: a cohort analysis
por: Lexchin, Joel
Publicado: (2018)

Increase in Drug Spending in Canada Due to Extension of Data Protection for Biologics: A Descriptive Study
por: Lexchin, Joel
Publicado: (2019)

Complaints about Violations of Voluntary and Pharmaceutical Industry-Run Medicine Promotion Codes in Canada
por: Lexchin, Joel
Publicado: (2023)

How safe are new drugs? Market withdrawal of drugs approved in Canada between 1990 and 2009
por: Lexchin, Joel
Publicado: (2014)

Health Canada’s use of expedited review pathways and therapeutic innovation, 1995–2016: cross-sectional analysis
por: Lexchin, Joel
Publicado: (2018)

Postmarket safety in Canada: are significant therapeutic advances and biologics less safe than other drugs? A cohort study
por: Lexchin, Joel
Publicado: (2014)

Information about confirmatory studies required for new drugs conditionally approved by Health Canada: A cross-sectional study
por: Lexchin, Joel
Publicado: (2022)

Prediction of therapeutic value of new drugs approved by health Canada from 2011−2020: A cross-sectional study
por: Lexchin, Joel
Publicado: (2023)

New drug submissions in Canada and a comparison with the Food and Drug Administration and the European Medicines Agency: Cross-sectional analysis
por: Lexchin, Joel
Publicado: (2023)

Quality and Quantity of Information in Summary Basis of Decision Documents Issued by Health Canada
por: Habibi, Roojin, et al.
Publicado: (2014)

A comparison of the Food and Drug Administration’s and Health Canada’s regulatory decisions about failed confirmatory trials for oncology drugs: an observational study
por: Lexchin, Joel
Publicado: (2021)

Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study
por: Lexchin, Joel
Publicado: (2018)

Pharmaceutical security for Canada
por: Lee, Shoo K., et al.
Publicado: (2022)

CETA and pharmaceuticals: impact of the trade agreement between Europe and Canada on the costs of prescription drugs
por: Lexchin, Joel, et al.
Publicado: (2014)

A call for a national ART registry
por: Al-Jaroudi, Dania
Publicado: (2016)

Sécurité d’approvisionnement pharmaceutique au Canada
por: Lee, Shoo K., et al.
Publicado: (2022)

How well do Canadian media outlets convey medical treatment information?: Initial findings from a year and a half of media monitoring by Media Doctor Canada
por: Cassels, Alan, et al.
Publicado: (2008)

Assessment of Price and Clinical Benefit of Cancer Drugs in Canada, 2011-2020
por: Jenei, Kristina, et al.
Publicado: (2023)

Tozinameran vaccination in Canada: no change in benefit-risk profile
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_tqulkpkb0208k5qiemrs0r3i5q